Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865396 | 1.00 | PIK3CD (0.41) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864056 | 0.84 | CD274 (0.38) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864057 | 0.84 | CD274 (0.38) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864914 | 0.84 | PIK3CD (0.44) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864916 | 0.84 | PIK3CD (0.44) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864020 | 0.83 | PIK3CD (0.40) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864019 | 0.83 | PIK3CD (0.40) | PIK3CDCD274PDCD1LG2IRAK4IRAK1 | |
| SCHEMBL864023 | 0.83 | CD274 (0.46) | CD274PDCD1LG2IRAK4IRAK1PDCD1 | |
| SCHEMBL864022 | 0.83 | CD274 (0.46) | CD274PDCD1LG2IRAK4IRAK1PDCD1 | |
| SCHEMBL3791850 | 0.83 | CD274 (0.46) | CD274PDCD1LG2IRAK4IRAK1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885CD274 2278/4885PDCD1LG2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.